Division of Microbiology and Immunology, Department of Pathology, University of Utah, Salt Lake City, Utah, United States.
Molecular Medicine Program, University of Utah, Salt Lake City, Utah, United States.
Hamostaseologie. 2022 Aug;42(4):221-228. doi: 10.1055/a-1646-3392. Epub 2021 Dec 8.
Coronavirus disease 2019 (COVID-19) encompasses a broad spectrum of clinical manifestations caused by infection with severe acute respiratory syndrome coronavirus 2.Patients with severe disease present with hyperinflammation which can affect multiple organs which often include observations of microvascular and macrovascular thrombi. COVID-19 is increasingly recognized as a thromboinflammatory disease where alterations of both coagulation and platelets are closely linked to mortality and clinical outcomes. Although platelets are most well known as central mediators of hemostasis, they possess chemotactic molecules, cytokines, and adhesion molecules that are now appreciated as playing an important role in the regulation of immune response. This review summarizes the current knowledge of platelet alterations observed in the context of COVID-19 and their impact upon disease pathobiology.
新型冠状病毒病 2019(COVID-19)是由严重急性呼吸综合征冠状病毒 2 感染引起的广泛临床症状。重症患者表现出过度炎症,可影响多个器官,其中经常观察到微血管和大血管血栓。COVID-19 越来越被认为是一种血栓炎症性疾病,其中凝血和血小板的改变与死亡率和临床结局密切相关。尽管血小板最常被认为是止血的中心介质,但它们具有趋化因子、细胞因子和粘附分子,现在被认为在调节免疫反应中起着重要作用。这篇综述总结了 COVID-19 背景下观察到的血小板改变及其对疾病病理生物学的影响的最新知识。